Alzheimer's Disease Education and Referral Center

Search for Clinical Trials

Your Search for state of New Jersey Identified 17 Trial(s):

  • 1. AC-1204 for Mild to Moderate Alzheimer's Disease

    Purpose: To evaluate the effects of AC-1204 on cognition, activities of daily living, quality of life, pharmacokinetic measures, and safety in people with mild to moderate Alzheimer's disease.

  • 2. Aspirin in Reducing Events in the Elderly (ASPREE)

    Purpose: To examine whether the potential benefits of low-dose aspirin outweigh the risks in people over age 70.

  • 3. AVP-923 for Treatment of Agitation in Alzheimer's Patients

    Purpose: To evaluate the safety, tolerability, and efficacy of AVP-923 (dxtromethorphan/qinidine) for the treatment of agitation in people with Alzheimer's disease.

  • 4. BAN2401 for Early Alzheimer's Disease

    Purpose: To determine the effectiveness of the experimental drug BAN2401 as a possible treatment for people with mild cognitive impairment or mild Alzheimer's disease.

  • 5. BIIB037 in Prodromal or Mild Alzheimer's Disease

    Purpose: To evaluate the safety and tolerability of BIIB037 in people with prodromal or mild Alzheimer's disease.

  • 6. Combination Treatment Study for Memory Impairment and Depression

    Purpose: To determine the response of older adults with both depression and cognitive impairment to donepezil vs. placebo after treatment with antidepressants. The goal is improve cognition and delay conversion to dementia.

  • 7. Dominantly Inherited Alzheimer Network (DIAN)

    Purpose: To identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

  • 8. ELND005 for Agitation and Aggression in Alzheimer's Disease

    Purpose: To determine whether ELND005 is effective in treating symptoms of agitation and aggression in people with Alzheimer's disease.

  • 9. Gantenerumab for Prodromal Alzheimer's Disease

    Purpose: To evaluate the safety and efficacy of the experimental drug gantenerumab on cognition and functioning in people with prodromal (very early stage) Alzheimer's disease.

  • 10. Home-Delivered Intervention for Depressed, Cognitively Impaired Elders

    Purpose: To test the efficacy of Problem Adaptation Therapy (PATH), a home-delivered psychosocial intervention for elders with major depression, memory problems, and disability.

  • 11. Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)

    Purpose: To determine whether positron emission tomography (PET) scanning can help distinguish patients with early Alzheimer's changes in their brains from those having other causes of cognitive impairment more accurately than current clinical practices.

  • 12. MK-8931 for Mild to Moderate Alzheimer's Disease

    Purpose: To assess the efficacy and safety of MK-8931 as a possible treatment for Alzheimer's disease.

  • 13. Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil

    Purpose: To determine if difficulty with the sense of smell can predict conversion from mild cognitive impairment to Alzheimer's disease and track response to donepezil therapy.

  • 14. RO4602522 in Patients with Moderate Alzheimer Disease on Donepezil or Rivastigmine Therapy

    Purpose: To evaluate the efficacy and safety of RO4602522 in people with moderate-stage Alzheimer disease who take donepezil or rivastigmine.

  • 15. Systolic Blood Pressure Intervention Trial: Memory and Cognition in Decreased Hypertension (SPRINT-MIND)

    Purpose: To determine whether intensive blood pressure lowering will reduce the incidence of all-cause dementia, reduce the decline of global cognitive function in key specific domains, and show changes in brain structure.

  • 16. TRx0237 for Mild Alzheimer's Disease

    Purpose: To determine the safety and efficacy of the experimental drug TRx0237 to treat people with mild Alzheimer's disease.

  • 17. TRx0237 for Mild to Moderate Alzheimer's Disease

    Purpose: To determine the safety and efficacy of the experimental drug TRx0237 to treat people with mild to moderate Alzheimer's disease.

  • Return to AD Clinical Trials Search Results

    Return to AD Clinical Trials Home

    Refine Your Search

    Type in a word or phrase such as drug name,
    disease stage, or trial name
    Input a city and state or zip code
    Enter the distance in number of miles from the location
    (default is 50)
    Age of the participant